Epoch Investment Partners Inc. Has $39.68 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Epoch Investment Partners Inc. reduced its holdings in Vertex Pharmaceuticals by 5.4%, now owning 81,836 shares valued at approximately $39.68 million.
• The company's stock is currently rated as a "Moderate Buy" based on analyses from multiple brokerages, with an average target price of $497.10.
• Vertex Pharmaceuticals reported a quarterly revenue of $2.94 billion, exceeding analyst estimates, and an earnings per share (EPS) of $4.52.

Epoch Investment Partners Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,836 shares of the pharmaceutical company's stock after selling 4,641 shares during the quarter. Epoch Investment Partners Inc.'s holdings in Vertex Pharmaceuticals were worth $39,676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Clal Insurance Enterprises Holdings Ltd increased its position in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $31,000. SJS Investment Consulting Inc. increased its position in Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after buying an additional 30 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Vertex Pharmaceuticals in the 1st quarter valued at about $46,000. Finally, Stone House Investment Management LLC bought a new stake in Vertex Pharmaceuticals in the 1st quarter valued at about $48,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VRTX. Guggenheim decreased their target price on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. HC Wainwright decreased their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating for the company in a research report on Tuesday, August 5th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. BMO Capital Markets set a $530.00 target price on Vertex Pharmaceuticals and gave the company an "outperform" rating in a research report on Tuesday, August 5th. Finally, Erste Group Bank lowered Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have issued a Hold rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $497.10.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $387.18 on Wednesday. The stock has a 50 day moving average price of $436.66 and a two-hundred day moving average price of $460.13. The firm has a market capitalization of $99.27 billion, a P/E ratio of 27.68 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company's revenue for the quarter was up 11.3% on a year-over-year basis. During the same period in the previous year, the company posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.